$7.96
2.31% yesterday
NYSE, Jun 12, 10:07 pm CET
ISIN
US03168L1052
Symbol
AMRX
Sector
Industry

Amneal Pharmaceuticals, Inc. Class A Stock price

$7.96
+0.36 4.74% 1M
+0.04 0.51% 6M
+0.04 0.51% YTD
+0.85 11.96% 1Y
+3.48 77.68% 5Y
-39.12 83.09% 10Y
+3.29 70.45% 20Y
NYSE, Closing price Thu, Jun 12 2025
+0.18 2.31%
ISIN
US03168L1052
Symbol
AMRX
Sector
Industry

Key metrics

Market capitalization $2.49b
Enterprise Value $4.97b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 23.76
EV/Sales (TTM) EV/Sales 1.76
P/S ratio (TTM) P/S ratio 0.88
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $2.83b
EBIT (operating result TTM) EBIT $364.21m
Free Cash Flow (TTM) Free Cash Flow $209.20m
Cash position $59.19m
EPS (TTM) EPS $-0.04
P/E forward 56.86
P/S forward 0.83
EV/Sales forward 1.65
Short interest 2.09%
Show more

Is Amneal Pharmaceuticals, Inc. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Amneal Pharmaceuticals, Inc. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast:

Buy
100%

Financial data from Amneal Pharmaceuticals, Inc. Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2,830 2,830
-
100%
- Direct Costs 1,792 1,792
-
63%
1,038 1,038
-
37%
- Selling and Administrative Expenses 489 489
-
17%
- Research and Development Expense 191 191
-
7%
661 661
-
23%
- Depreciation and Amortization 296 296
-
10%
EBIT (Operating Income) EBIT 364 364
-
13%
Net Profit -13 -13
-
0%

In millions USD.

Don't miss a Thing! We will send you all news about Amneal Pharmaceuticals, Inc. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amneal Pharmaceuticals, Inc. Class A Stock News

Neutral
GlobeNewsWire
about 21 hours ago
BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of prednisolone acetate ophthalmic suspension, 1% sterile which references Pred Forte®. Pred Forte and its design are trademarks of Allergan, Inc., an AbbVie company. Launch of this product is planned for the third qua...
Neutral
GlobeNewsWire
15 days ago
BRIDGEWATER, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) will participate in two upcoming investor conferences: Jefferies Global Healthcare Conference on June 5, 2025, with company presentation at 9:20 AM ET, and Goldman Sachs Global Healthcare Conference on June 10, 2025, with fireside chat at 10:40 AM ET. Chirag Patel, Co-Chief Executive Officer and Pres...
Positive
Reuters
29 days ago
Amneal Pharmaceuticals said on Thursday the U.S. Food and Drug Administration has approved its self-administered migraine drug.
More Amneal Pharmaceuticals, Inc. Class A News

Company Profile

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Head office United States
CEO Chintu Patel
Employees 8,300
Founded 2002
Website amneal.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today